50 mg
Sponsors
Pfizer Inc., Medical University Of Lodz, Centrum Medyczne Ksztalcenia Podyplomowego, Medical University Of Gdansk, Medical University Of Warsaw
Conditions
Acute ischemic strokeAlopecia areataAttention-deficit hyperactivity disorderCHRONIC SPONTANEOUS URTICARIACompulsive Sexual Behaviour DisorderDepressive-anxiety states in people with heart failure with preserved ejection fractionMyocarditisType 1 diabetes
Phase 2
LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.
Active, not recruitingCTIS2023-506862-30-00
Start: 2024-11-24Target: 150Updated: 2025-08-25
A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote
RecruitingCTIS2024-518509-17-00
Start: 2022-01-10Target: 300Updated: 2024-12-09
B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria
Not yet recruitingCTIS2025-522642-44-00
Target: 7Updated: 2026-02-25
Phase 3
B7981080 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO
Active, not recruitingCTIS2022-502518-98-00
Start: 2024-04-26Target: 355Updated: 2025-11-24
Pharmacological treatment of compulsive sexual behaviour disorder
WithdrawnCTIS2024-514490-22-00
Target: 410Updated: 2024-09-30
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved ejection fraction
CompletedCTIS2024-515061-33-00
Start: 2024-03-22End: 2025-12-05Target: 485Updated: 2025-07-24
B7981094 - A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO‑CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA
Active, not recruitingCTIS2024-519370-40-00
Start: 2025-07-16Target: 74Updated: 2025-11-06